Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.71 |
| ▸ | CA2 | P00918 | 7/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133953 | 0.86 | CA1 (0.75) | CA1CA2ALDH1A1SIGMAR1GBA1 | |
| SCHEMBL6323468 | 0.84 | GBA1 (0.70) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6329766 | 0.83 | CA1 (0.73) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6323694 | 0.83 | CA1 (0.71) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6326226 | 0.83 | CA1 (0.53) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6324078 | 0.83 | SIGMAR1 (0.51) | CA1CA2ALDH1A1SIGMAR1GBA1 | |
| SCHEMBL6323680 | 0.82 | GBA1 (0.57) | CA1CA2ALDH1A1GBA1 | |
| SCHEMBL6329695 | 0.81 | ALDH1A1 (0.57) | CA1CA2ALDH1A1GBA1TSHR | |
| SCHEMBL6329622 | 0.80 | ALDH1A1 (0.61) | CA1CA2ALDH1A1MMP1MMP2 | |
| SCHEMBL6328744 | 0.80 | CA1 (0.55) | CA1CA2ALDH1A1GBA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | PHARMACIA CORPORATION | 2005-01-20 | — | — | US | disclosed |
| US-6747027-B1 | SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 | PHARMACIA CORPORATION | 2004-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014840-A1 | Thiol sulfonamide metalloprotease inhibitors | MMP12, MMP13, MMP3 | CA1 196/4885CA2 492/4885ALDH1A1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.